ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Palivizumab

Also written as “Palivizumab 15 mg/kg”, “Lyophilized Palivizumab” and “Liquid Palivizumab”.

Its studies are mostly in Respiratory Syncytial Virus Infections · Bronchopulmonary Dysplasia · Bronchiolitis, led by 5 companies.

Drug pagePalivizumab: every studyMany companies study it; this page follows only the 9 they lead. All 10 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 3, 20059 company-led studies, 1 open or runningNext primary completion: Feb 28, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only41 open or runningphase 4since Oct 3, 2005Oct 3, 2005Feb 28, 2027NCT06851806
AbbVieits history only20 open or runningphase 3since Sep 12, 2011Sep 12, 2011none ahead
Abbott10 open or runningphase 3since Nov 2, 2009Nov 2, 2009none ahead
Fresenius Kabiits history only10 open or runningphase 1since Jul 24, 2020Jul 24, 2020none ahead
Hamad Medicalits history only10 open or runningphase 3since May 10, 2015May 10, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Abbott only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 2009First study: phase 3 study in Respiratory Syncytial Virus InfectionsFirst studyNCT01006629 · 100 enrolled · Russian Federation

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Fusion glycoprotein F0 inhibitor”ChEMBL 37, by rule

Studies

The one study Abbott leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01006629Respiratory Syncytial Virus Infections · Russian Federation3CompletedApr 2010100

How it is read

Names in the registry

  • “Palivizumab”, 4 entries
  • “Palivizumab 15 mg/kg”, 1 entry
  • “Lyophilized Palivizumab”, 1 entry
  • “Liquid Palivizumab”, 1 entry
  • “Motavizumab, palivizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.